Dyspnoea | 54–98% [18] | |
Fatigue | 8–29% [18] | Pulmonary rehabilitation Supplemental oxygen
|
Anxiety and depression | 14–50% [17, 18] | |
Cough | 59–100% [18] | Treat exacerbating factors, e.g. proton pump inhibitors for gastro-oesophageal reflux Pirfenidone Thalidomide (significant toxicity) Target cough reflex with gabapentin or amitriptyline Inhaled sodium cromoglycate (trial currently ongoing; clinicaltrials.gov, NCT03864328)
|